Insight Molecular Diagnostics (IMDX) announced attendance at two key industry conferences where it will discuss its GraftAssur technology, including its clinical kitted test under development. “Kidney transplant management is changing. Emerging medications such as anti-CD38 therapies have a chance at treating transplant rejection, and in-house testing will bring care where it belongs – closer to the patient,” said iMDx CEO Josh Riggs. “Our presentations this fall in both Singapore and Orlando highlight the bright potential of our technology and the strong global interest in our assay.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics Approves Executive Salary Increases
- Insight Molecular Diagnostics announces novel registry database
- Insight Molecular Diagnostics enrolls first patient in GraftAssureDx trial
- OncoCyte Corp’s Earnings Call: Progress Amid Challenges
- Hold Rating for Insight Molecular Diagnostics Amid Strategic Expansion and Market Challenges